The Cigna Group
CI: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$876.00 | Nxylrjq | Bplfvywq |
Cigna: Mildly Boosts Growth Goal and Defends Capital Allocation Plan on Specialty Pharmacy Strength
At its investor day, narrow-moat Cigna's management mildly increased its long-term adjusted earnings growth goal (to 10%-14% from 10%-13%) primarily on tailwinds in its specialty pharmacy business. While we appreciate those trends, we are raising our fair value estimate to $366 per share from $344 primarily because of cash flows generated since our last valuation update in May 2023. Shares remain fairly valued.